Please login to the form below
NCI
This page shows the latest NCI news and features for those working in and with pharma, biotech and healthcare.
BMS Foundation announces Robert A Winn Diversity in Clinical Trials Award Program
Robert A Winn is the first African-American director of a National Cancer Institute (NCI)-designated cancer centre. ... He has received numerous honours and awards, including the NCI Center to Reduce Cancer Health Disparities Continuing Umbrella of
Latest news
-
AZ’s comeback drug cediranib stumbles in phase 3 trial
A phase 2 NCI trial reported in 2014 showed that cediranib plus Lynparza was able to nearly double progression-free survival (PFS) compared to Lynparza alone in patients who had either ... The NCI is carrying out the phase 2/3 GY005 trial of Lynparza
-
Merck chases Roche with triple-negative breast cancer data for Keytruda
KEYNOTE-242 is a National Cancer Institute (NCI) sponsored trial testing adjuvant use of the checkpoint inhibitor after neoadjuvant chemotherapy due to generate results in 2026.
-
FDA will maintain the pace, vows Woodcock, but warns of skills gap
His successor, Ned Sharpless has been drafted in from his former role as head of the National Cancer Institute (NCI), but remains for now an interim Commissioner, and one certainly less
-
Iovance up on good ASCO abstract data for cervical cancer therapy
Iovance’s approach to immunotherapy was pioneered by Steven Rosenberg of the US National Cancer Institute (NCI).
-
Bluebird’s myeloma CAR-T safety ‘could support outpatient use’
responses with a manageable safety profile we’ve seen for bb2121 to date,” said the trial’s principal investigator James Kochenderfer of the US National Cancer Institute (NCI).
More from news
Approximately 1 fully matching, plus 32 partially matching documents found.
Latest Intelligence
-
The challenges of identifying rare diseases
Two recent studies, however, have identified more than 10, 000 rare diseases by computing and harmonising rare disease information from multiple data sources such as Orphanet, OMIM, GARD, DOID and NCI
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
Selumetinib was given ‘breakthrough therapy’ status and rapidly green-lit by the FDA last month (April) following a promising National Cancer Institute (NCI) Cancer Therapy Evaluation Program sponsored phase 2 trial. ... Collaborating with our
-
Staying ahead in the era of precision medicine
For example, Lung-MAP, a large-scale umbrella trial in non-small cell lung cancer, was one of the first to involve partnerships between several groups including the FDA, NCI, advocacy
-
Country report: The healthcare market in France
National Cancer Institute (NCI) or the National Institute for Prevention and Education for Health (NIPEH).
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
AZ and Medimmune bolsters immuno-oncology leadership
roles at the National Cancer Institute (NCI).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
ASCO 2015: What you missed in Chicago
The second area that really impressed me was the large National Cancer Institute (NCI) trial[3] that will look to treat patients with solid tumours based on their genetic mutations and ... Larkin et al 2015 NEJM[3] NCI Prepares to Launch MATCH Trial.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Takeda’s dengue vaccine receives MHRA approval for those aged four years and older
- Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis
- Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients
- NHS urges people yet to receive their COVID-19 booster to come forward
- Biosimilars and beyond: innovating for improved patient outcomes
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Why female mentorship is so powerful in pharma
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Digital technology: a significant change in healthcare innovation
- Assessing the value of interim analyses in clinical trials
PMHub
Evoke Kyne
Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...
Latest intelligence
- Biosimilars and beyond: innovating for improved patient outcomes
- How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
